AXDX Accelerate Diagnostics, Inc revenue, earnings and financials
For the quarter ended December 31, 2024, Accelerate Diagnostics, Inc reported revenue of $2.82M (down 7.0% from a year earlier), net income of −$9.59M and diluted EPS of n/a; over the last four quarters revenue was $11.7M and net income −$50.0M; for the fiscal year ended December 2024 revenue was $11.7M, down 3.0% on the year before.
AXDX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $11.7M, gross profit $2.70M, operating income −$35.3M, net income −$50.0M (margin -427.8%), EPS −$2.15
- Fiscal year ended Dec 2023: revenue $12.1M, gross profit $2.55M, operating income −$54.0M, net income −$61.6M (margin -511.0%), EPS −$4.94
- Fiscal year ended Dec 2022: revenue $12.8M, gross profit $3.30M, operating income −$62.8M, net income −$62.5M (margin -490.1%), EPS −$7.61
- Fiscal year ended Dec 2021: revenue $11.8M, gross profit −$381K, operating income −$71.6M, net income −$77.7M (margin -659.5%), EPS −$12.59
AXDX quarterly revenue and earnings
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.82M (down 7.0% year over year), net income −$9.59M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $2.98M (down 9.8% year over year), net income −$14.6M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $2.99M (up 2.2% year over year), net income −$11.6M, EPS −$0.50
- Quarter ended Mar 31, 2024: revenue $2.92M (up 3.9% year over year), net income −$14.2M, EPS −$0.74
- Quarter ended Dec 31, 2023 (from the annual report): revenue $3.03M (up 1.8% year over year), net income −$13.0M, EPS −$0.32
- Quarter ended Sep 30, 2023: revenue $3.30M (up 11.5% year over year), net income $910K, EPS $0.06
- Quarter ended Jun 30, 2023: revenue $2.92M (down 24.3% year over year), net income −$32.7M, EPS −$2.97
- Quarter ended Mar 31, 2023: revenue $2.81M (down 4.9% year over year), net income −$16.8M, EPS −$1.71
- Quarter ended Dec 31, 2022: revenue $2.97M (down 11.1% year over year), net income −$14.6M, EPS −$0.14
- Quarter ended Sep 30, 2022: revenue $2.96M (down 5.2% year over year), net income −$15.9M, EPS −$1.83
- Quarter ended Jun 30, 2022: revenue $3.86M (up 38.0% year over year), net income −$18.5M, EPS −$2.43
- Quarter ended Mar 31, 2022: revenue $2.96M (up 17.5% year over year), net income −$13.5M, EPS −$0.20
- Quarter ended Dec 31, 2021: revenue $3.34M, net income −$22.8M, EPS −$0.34
- Quarter ended Sep 30, 2021: revenue $3.12M, net income −$8.99M, EPS −$0.15
- Quarter ended Jun 30, 2021: revenue $2.80M, net income −$21.7M, EPS −$0.36
- Quarter ended Mar 31, 2021: revenue $2.52M, net income −$24.2M, EPS −$0.41
AXDX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$24.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$40.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$48.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$47.3M, share buybacks n/a
AXDX balance sheet
- Dec 31, 2024: cash $15.1M, total assets $28.6M, total liabilities $84.6M, shareholders' equity −$56.0M
- Sep 30, 2024: cash $19.7M, total assets $32.3M, total liabilities $80.8M, shareholders' equity −$48.5M
- Jun 30, 2024: cash $8.59M, total assets $22.9M, total liabilities $57.8M, shareholders' equity −$34.9M
- Mar 31, 2024: cash $14.6M, total assets $30.7M, total liabilities $56.5M, shareholders' equity −$25.8M
- Dec 31, 2023: cash $12.1M, total assets $31.4M, total liabilities $51.3M, shareholders' equity −$19.9M
- Sep 30, 2023: cash $20.2M, total assets $39.3M, total liabilities $74.4M, shareholders' equity −$35.0M
- Jun 30, 2023: cash $29.3M, total assets $49.9M, total liabilities $88.5M, shareholders' equity −$38.7M
- Mar 31, 2023: cash $29.4M, total assets $51.0M, total liabilities $89.7M, shareholders' equity −$38.7M
What is AXDX's revenue?
Accelerate Diagnostics, Inc reported $11.7M of revenue over its last four quarters, through December 31, 2024.
Is AXDX profitable?
No. Accelerate Diagnostics, Inc lost $50.0M over the last four quarters.